3. Heidary M, Khosravi AD, Khoshnood S, et al. Daptomycin. J Antimicrob Chemother. 2018 Jan 1;73(1):1-11. https://doi.org/10.1093/jac/dkx349
4. Tótoli EG, Garg S, Salgado HR. Daptomycin: Physicochemical, Analytical, and Pharmacological Properties. Ther Drug Monit. 2015 Dec;37(6):699-710.
6. Principi N, Caironi M, Venturini F, et al. Daptomycin in paediatrics: current knowledge and the need for future research. J Antimicrob Chemother. 2015 Mar;70(3):643-8. https://doi.org/10.1093/jac/dku453
11. Taylor SD, Palmer M. The action mechanism of daptomycin. Bioorg Med Chem. 2016 Dec 15;24(24):6253-6268. https://doi.org/10.1016/j.bmc.2016.05.052
12. U.S. Food & Drug Administration. Cubicin (Daptomycin) Injection Printed Labeling, 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s055lbl.pdf
13. Ogami C, Tsuji Y, Kasai H, et al. Evaluation of pharmacokinetics and the stability of daptomycin in serum at various temperatures. Int J Infect Dis. 2017 Apr;57:38-43. https://doi.org/10.1016/j.ijid.2017.01.017
14. Xu X, Khadzhynov D, Peters H, et al. Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy. Br J Clin Pharmacol. 2017 Mar;83(3):498-509. https://doi.org/10.1111/bcp.13131